Clinical trials: Neisseria Meningitidis
Haemophilus Influenzae Type b, Neisseria Meningitidis
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are…
- Trial name
- NCT00289783
- Testing
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB
- Where
- 93 sites in United States, Australia and 1 more
- Volunteers
- 4,441 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal Infection
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers
This study is aimed at studying quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) formulations in Toddlers.
- Trial name
- NCT00631995
- Testing
- Meningococcal Polysaccharide Tetanus Protein Conjugate, Meningococcal polysaccharide group C conjugated
- Where
- 5 sites in Australia
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Meningococcal
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.
- Trial name
- NCT01235975
- Testing
- Meningococcal vaccine GSK 134612, MencevaxACWY TM
- Where
- Lebanon
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccination With MenbVac
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)
This study aims to estimate the vaccinal immunity four years after four doses of MenbVac in children aged 4-8 years.
- Trial name
- Exten MenbVac (NCT01565577)
- Testing
- MenbVac
- Where
- France
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Neisseria Meningitidis
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine.
- Trial name
- NCT07197762
- Testing
- Trumenba, PENBRAYA
- Where
- 2 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Emory University
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age
This is a clinical study to assess the safety, tolerance and immunogenic response to MCV4(quadrivalent meningococcal polysaccharide conjugate, meningococcal serogroups A,C,Y, and W135), Tdap (diphtheria, tetanus, and acellular…
- Trial name
- NCT01461980
- Testing
- rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline
- Where
- 117 sites in United States
- Volunteers
- 2,648 people, healthy volunteers welcome
- Sponsor
- Pfizer
Serogroup C Meningococcal Meningitis
Conjugate Vaccine Against Meningococcus C a Brazilian Project
TYPE / DESIGN STUDY: Clinical trial phase II / III, randomized, double-blind, national multi-center, with a total of 1,644 research participants stratified into 3 groups according to age for starting of the primary vaccination…
- Trial name
- NCT02858570
- Testing
- MenCC-BIO Vaccine, Combined - CRM197
- Where
- Brazil
- Volunteers
- 1,644 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Meningococcal Disease
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
A multicenter, single arm, postmarketing surveillance study. This study is a postlicensure requirement of the Philippine Food and Drug Administration (FDA) to provide continued safety evaluation of MenACWY-CRM in Philippine…
- Trial name
- NCT01705379
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Vaccination, Rotavirus Infections
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
A two-phases study will be carried out with the following aims 1. st phase (2018-2020) To investigate the vaccination coverage for Rotavirus vaccine (RV) in Campania Region together with other pediatric vaccinations scheduled in…
- Conditions
- Vaccination, Rotavirus Infections, Meningococcal Infections
- Trial name
- STORM (NCT05212935)
- Testing
- Rotavirus Vaccine
- Volunteers
- 2,000 people
- Sponsor
- Federico II University
Neisseria Meningitidis, Meningococcal Infections
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine.
- Trial name
- NCT00444951
- Testing
- Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine, Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
- Where
- 7 sites in Saudi Arabia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Haemophilus Influenzae Type b, Neisseria Meningitidis
Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants
The purpose of this Phase IIIb study is to evaluate the immunogenicity, reactogenicity \& safety of GSK Biologicals' Hib-MenC vaccine (Menitorix™) when co-administered with GSK Biologicals' DTPa-HBV-IPV vaccine (Infanrix™ penta)…
- Trial name
- NCT00586612
- Testing
- Menitorix™, Infanrix™ penta, Prevenar™
- Where
- 8 sites in Spain
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitidis, Haemophilus Influenzae Type b
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vaccine compared to control groups receiving licensed Hib or MenC conjugate vaccines, each administered at 2, 4, 6, and 12 to 15 months of age.
- Trial name
- NCT00134719
- Testing
- MenHibrix (Hib-MenCY-TT), Infanrix® Penta, Prevenar®
- Where
- 3 sites in Australia
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcemia
Immunology and Safety of Menactra® in Children in Saudi Arabia
This study will be conducted among children in Saudi Arabia who previously received two doses of A, C, Y, W-135 polysaccharide vaccine before the age of 2 years, and in meningococcal vaccine-naïve children (Control Group).
- Trial name
- NCT00539032
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
This study will investigate the breadth of protection against meningococcal disease in humans immunized with a newly FDA approved meningococcal B vaccine, trade name "Trumenba®" manufactured by Pfizer Vaccines.
- Trial name
- NCT02569632
- Testing
- Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland